پديد آورندگان :
Dehghanifard، Ali نويسنده Department of Laboratory Sciences, Faculty of Medicine, Islamic Azad University, Tehran Medical Branch, Tehran, Iran Dehghanifard, Ali , Kaviani، Saeid نويسنده , , Noruzinia، Mehrdad نويسنده , , Soleimani، Masoud نويسنده , , Abroun، Saeid نويسنده Hematology Department, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran , , Hajifathali، Abbas نويسنده , , Pourfathollah، Ali Akbar نويسنده , , Mortazavi، Yousef نويسنده , , Ahmadvand، Mohammad نويسنده Department of Laboratory Sciences, Zahedan University of Medical Sciences, Zahedan, Iran Ahmadvand, Mohammad , Mahmoodinia-Meymand، Maryam نويسنده Department of Biology, Stem cell Research Center, Sarem Hospital, Tehran, Iran Mahmoodinia-Meymand, Maryam , Kaviani، Zeinab نويسنده Department of Internal Medicine, Alborz University of Medical Sciences, Karaj, Iran Kaviani, Zeinab , Farshdousti Hagh، Majid نويسنده Department of Hematology, Tarbiat Modares University, Tehran, Iran , , Saki، Najmaldin نويسنده Department of Hematology and Blood Banking School of Medical Sciences, Tarbiat Modares University, Tehran, Iran ,
چكيده لاتين :
Background: The use of drugs with the ability to induce production of fetal hemoglobin as a novel therapeutic approach in treating B-Hemoglobinopathies is considered. ?-globin gene expression inducer drugs including sodium butyrate and thalidomide can reduce additional ?-globin chains accumulation in erythroid precursors.
Materials and Methods: In this experimental study, MACS kit was used to isolate CD133+ cells of umbilical cord blood. Further, the effect of two drugs of thalidomide and sodium butyrate were separately and combined studied on the induction of quantitative expression of B-globin and ?-globin genes in erythroid precursor cells derived from CD133+ stem cells in-vitro. For this purpose, the technique SYBR green Real-time PCR was used.
Results: Flow cytometry results showed that approximately 95% of purified cells were CD133+. Real-time PCR results also showed the increased levels of ?-globin mRNA in the cell groups treated with thalidomide, sodium butyrate and combination of drugs as 2.6 and 1.2 and 3.5 times respectively, and for B-globin gene, it is respectively 1.4 and 1.3 and 1.6 times compared with the control group (p < 0.05).
Conclusion: The study results showed that the mentioned drug combination can act as a pharmaceutical composition affecting the induction of fetal hemoglobin expression in erythroid precursor cells derived from CD133 + cells.
